A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospital

BACKGROUND: Cyclooxygenase-2 inhibitors (COX-2-Is) have recently been concerned in the occurrence of adverse cardiovascular (CV) events. Rofecoxib and valdecoxib has been withdrawn from the market, but celecoxib, etoricoxib and parecoxib continues to be used. Other nonsteroidal anti-inflammatory dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhosale, Uma A., Quraishi, Nilofar, Yegnanarayan, Radha, Devasthale, Dileep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178340/
https://www.ncbi.nlm.nih.gov/pubmed/25298608
http://dx.doi.org/10.4103/0300-1652.140386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178340/
https://www.ncbi.nlm.nih.gov/pubmed/25298608
http://dx.doi.org/10.4103/0300-1652.140386

Ejemplares similares